Asthma

Asthma is a chronic respiratory condition characterized by inflammation of the airways, leading to symptoms such as episodic breathlessness, chest tightness, coughing, and wheezing. This condition affects a significant portion of the global population, with estimates indicating over 300 million individuals worldwide, including 24.6 million in the USA^[1].

Biological Basis

The risk of developing asthma is influenced by a complex interplay of both genetic predispositions and environmental factors. Studies on twins suggest a substantial genetic component, with heritability estimates ranging from 35% to 90%^[2]. Genetic research, particularly through genome-wide association studies (GWAS), has been instrumental in identifying genetic variations associated with asthma susceptibility. These studies systematically explore candidate single nucleotide polymorphisms (SNPs) and genes, such as the ORMDL3 locus. While GWAS can reveal important genetic links, many identified SNPs often explain only a small fraction of the overall genetic risk.

Clinical Relevance

Beyond its impact on individual health, asthma carries a substantial clinical and economic burden. The morbidity and economic costs associated with asthma are comparable to those of other common chronic diseases^[3]. In the United States, asthma-related healthcare costs are estimated to be US$56 billion annually^[3]. Effective management of asthma is crucial for improving quality of life and reducing healthcare expenditures.

Social Importance

Asthma presents significant public health challenges, including notable disparities in prevalence, morbidity, mortality, and response to medications across different racial and ethnic groups. For instance, in the USA, prevalence rates vary, with 7.8% among European-Americans, 11.1% in African-Americans, and up to 16.6% in Hispanic-Americans^[4]. These disparities are thought to arise from a combination of factors, including differences in lifestyle, socioeconomic status, and potentially underlying population genetic variation. Understanding these multifaceted influences is vital for developing targeted prevention strategies and equitable healthcare interventions.

Limitations in Asthma Genetics Research

Understanding the genetic underpinnings of asthma is crucial, yet the field faces several inherent limitations that impact the interpretation and generalizability of research findings. These challenges stem from study design, population diversity, and the complex nature of the disease itself. Acknowledging these limitations is essential for guiding future research toward more comprehensive and impactful discoveries.

Challenges in Genetic Discovery and Replication

A primary limitation in asthma genetics research is often the sample size available for genome-wide association studies (GWAS) and subsequent replication efforts. Many studies are underpowered to detect genetic variants with smaller effect sizes, leading to the potential for missing true associations that contribute subtly to asthma risk. While stronger effects may be detectable, the inherent uncertainty regarding the magnitude of effect sizes across different populations further complicates the interpretation of replication failures, making it difficult to discern whether a lack of replication is due to insufficient statistical power or genuine population-specific genetic architectures.

Moreover, a significant number of observed genetic associations do not consistently replicate across various studies, which can be attributed to differences in statistical power and the heterogeneity of the populations examined. It is also possible that some initial findings reported in published GWAS represent false positives or spurious associations, underscoring the critical need for rigorous follow-up studies to validate findings and separate true genetic associations from chance discoveries. For polygenic traits like asthma, current sample sizes frequently remain a limiting factor in fully elucidating the spectrum of genetic risk factors.

Ancestry and Generalizability Limitations

Genetic studies of asthma have historically displayed a severe imbalance in population representation, with a vast majority conducted in individuals of European ancestry and a significant underrepresentation of globally diverse racial and ethnic minority groups. This lack of diversity severely restricts the generalizability of findings, as genetic variants exhibit differing allele frequencies and linkage disequilibrium patterns across distinct ancestral populations. Consequently, genetic associations identified predominantly in one population may not be applicable or have the same impact in others, thereby hindering a universal understanding of asthma susceptibility.

The limited inclusion of diverse populations also means that ethnic-specific loci, which may contribute significantly to asthma risk within particular groups, often remain undiscovered. For example, specific populations, such as individuals of Mexican descent, are largely under-studied in asthma genetics despite their size, leading to considerable knowledge gaps. These disparities not only impede the identification of all relevant genetic factors but also contribute to inequities in health outcomes by limiting the development of personalized diagnostic and therapeutic strategies tailored to specific populations.

Unaccounted Heritability and Complex Interactions

Despite compelling evidence for a strong genetic influence on asthma susceptibility, with heritability estimates ranging substantially from twin studies, genome-wide association studies have thus far identified only a small number of genetic loci with small to modest effects. Collectively, these identified loci explain only a minor portion of the overall genetic variation for asthma, indicating that a substantial amount of the disease’s heritability remains unexplained. This phenomenon, often termed “missing heritability,” suggests that current methodologies may not fully capture the intricate genetic architecture of asthma, which could involve numerous genes with very small individual effects, rare variants, or complex structural variations.

Asthma is recognized as a multi-factorial disease, profoundly influenced by complex interactions between genetic predispositions and various environmental factors. Traditional genetic analyses, often focusing on single markers, frequently fail to account for these intricate gene-environment confounders, resulting in an incomplete understanding of disease etiology. There is an increasing recognition for the adoption of more comprehensive analytical approaches, such as gene set or pathway-based analyses, which can integrate genetic signals at multiple levels without relying on arbitrary statistical significance thresholds. Such methods are crucial for extracting more functionally relevant and biologically sound information from genetic data, moving beyond individual markers to understand the broader biological context of asthma risk.

The intricate genetics of asthma involve a constellation of variants across numerous genes, many of which play critical roles in immune regulation and inflammatory responses. These genetic differences can influence an individual’s susceptibility to asthma and the severity of its presentation by altering gene expression, protein function, or immune cell interactions. Understanding these variants helps to elucidate the complex biological mechanisms underlying asthma.

The Major Histocompatibility Complex (MHC) region on chromosome 6 is a primary genetic hotspot for asthma, with genes likeHLA-DQA1, HLA-DQB1, and HLA-DRB1 being central to immune recognition. These genes encode proteins that present antigens to T-cells, initiating specific immune responses. Variants such as rs9272545 , rs9272346 , and rs28383454 within HLA-DQA1, along with rs2647025 , rs9273410 , and rs201184533 in HLA-DQB1, and those linking HLA-DQA1 with HLA-DQB1 (rs17843577 , rs28798705 , rs28407950 ) or HLA-DRB1 (rs9270911 , rs3104412 , rs9271365 ), can alter the specific antigens presented or modify the efficiency of immune signaling. These variations can lead to a heightened or dysregulated immune response to common allergens, driving the inflammation characteristic of asthma and allergic phenotypes. Studies indicate that associations in this region might stem from changes in gene expression levels, in addition to direct effects on antigen recognition^[5].

Further variants within the broader HLA region, including those involving HLA-DQB2 and HLA-DOB (e.g., rs7749543 , rs9276643 , rs2621363 ), also contribute to asthma susceptibility.HLA-DQB2 and HLA-DOB are involved in the processing and loading of peptides onto MHC class II molecules, influencing the diversity of antigens presented and the fine-tuning of immune responses. Additionally, variants like rs7755224 , rs1694112 , and rs79870097 , located between HLA-DQB1 and the pseudogene MTCO3P1(Mitochondrial Cytochrome C Oxidase Subunit 3 Pseudogene 1), may exert their effects by impacting regulatory elements that control the expression of adjacent functional immune genes, indirectly modulating asthma risk.

Key players in the allergic inflammatory cascade include IL1RL1 (Interleukin-1 Receptor Like 1, also known as ST2) and IL18R1 (Interleukin-18 Receptor 1), which are receptors for cytokines that promote type 2 immune responses. Variants such as rs3771180 , rs72823635 , and rs72823641 within the IL1RL1/IL18R1 locus can affect the signaling pathways initiated by these receptors, thereby influencing the intensity and duration of allergic inflammation in the airways. Similarly, the epithelial-derived alarmins IL33 (Interleukin-33) and TSLP (Thymic Stromal Lymphopoietin) are crucial initiators of allergic inflammation. Variants like rs992969 , rs7848215 , and rs3939286 near IL33 (linked with GTF3AP1) and rs1837253 , rs10455025 , and rs62375550 near TSLP (linked with BCLAF1P1) can alter the production or activity of these cytokines, significantly modulating the development and severity of asthma^[6].

Finally, the GSDMB (Gasdermin B) gene plays a role in regulating cell death and inflammation, and its variants, including rs2305479 , rs921650 , and rs1008723 , are strongly associated with asthma, particularly its more severe forms. These genetic variations inGSDMBare thought to influence the integrity of the airway epithelial barrier, modulate immune cell activation, and contribute to the inflammatory processes that lead to bronchial hyperresponsiveness and chronic allergic inflammation, representing a distinct pathway in asthma pathogenesis.

Classification, Definition, and Terminology

Asthma is a chronic respiratory condition generally characterized by a history of physician diagnosis of asthma and objective evidence of reversible airflow obstruction and/or bronchial hyperresponsiveness^[7].

Diagnostic Criteria

The general diagnostic approach for asthma includes identifying a history of physician diagnosis of asthma and conducting tests for reversible airflow obstruction and/or bronchial hyperresponsiveness^[7].

As an example of specific study criteria, the Childhood Asthma Management Program (CAMP) defined active asthma for trial inclusion based on:

• The presence of self-reported symptoms or inhaled bronchodilator use (not including pre-exercise use) an average of at least four times per week during the four weeks preceding the trial.
• Alternatively, the presence of diary-reported symptoms, inhaled bronchodilator use (not including pre-exercise use), or peak flows in the yellow zone an average of at least four times per week during the two-week run-in period to the clinical trial^[8].

Related Terminology

• Reversible Airflow Obstruction:A characteristic of asthma where the narrowing of the airways can be improved, often with therapeutic intervention^[7].
• Bronchial Hyperresponsiveness: Refers to an increased sensitivity and exaggerated narrowing of the airways in response to various triggers ^[7].

Signs and Symptoms

Asthma is generally diagnosed based on a history of physician diagnosis and objective tests for reversible airflow obstruction or bronchial hyperresponsiveness^[7].

Typical PresentationsIndividuals with asthma may experience symptoms associated with heightened airway reactivity. Some individuals with asthma may also experience acid reflux symptoms^[9].

Measurement ApproachesObjective measures of lung function are utilized for assessment. For example, the ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) and the percentage of predicted FEV1 are used for classifying asthma severity, particularly in adolescents^[10].

VariabilityThe presentation and severity of asthma can vary among individuals. Research indicates that predictors for general asthma symptoms can differ from those for severe asthma exacerbations in children^[11]. Additionally, diagnostic criteria for asthma may show inconsistencies across different studies or clinical settings^[7].

Causes

Asthma is a common chronic respiratory condition influenced by a combination of genetic and environmental factors.

Genetic FactorsGenetic predisposition plays a significant role in asthma susceptibility. Twin studies indicate a strong genetic component to asthma, particularly for childhood-onset asthma. Heritability estimates suggest that genetic factors account for 48–79% of the risk for asthma^[12]. The genetic landscape of asthma is complex, with research identifying numerous potential disease susceptibility genes and linkage regions^[13].

Environmental FactorsEnvironmental exposures can contribute to the development of asthma. Early-life exposure to air pollution has been linked to an increased risk of asthma, especially in minority children^[14].

Biological Background

Asthma is a chronic lung disease characterized by recurring periods of wheezing, chest tightness, shortness of breath, and coughing^[15]. These symptoms are mediated through airway inflammation and bronchoconstriction, which lead to airflow obstruction ^[15]. The disease is common, affecting 9% of the population in the United States, with prevalence continuing to rise globally^[16].

Genetic and Environmental Factors

Asthma development is influenced by an interaction of genetic and environmental factors^[17]. Twin studies indicate a strong genetic component, particularly for childhood asthma, with heritability estimates suggesting that 48–79% of asthma risk is attributable to genetic factors^[16]. Efforts to identify disease susceptibility genes have led to genome-wide linkage studies that have localized at least 20 linkage regions^[16]. Over 100 positional and biological candidate genes have been investigated for their roles in asthma^[16].

Molecular and Cellular Pathways

Recent advancements in molecular genetics are helping to uncover the genetic causes of asthma and pinpoint potential therapeutic targets^[18]. Large-scale surveys of DNA sequence variants have identified specific genes that influence asthma^[18]. These identified genetic variants are distributed across various chromosomes and are thought to impact lung function by altering key biochemical pathways ^[18].

Research has pointed to candidate genes involved in a pathway that initiates type 2 helper T-cell (Th2) inflammation in response to epithelial damage ^[16]. Other candidate genes may play a role in pathways that down-regulate airway inflammation and remodeling ^[16].

Specific genes associated with asthma or related traits include^[17]:

• ADAM33has been linked to asthma and bronchial hyperresponsiveness^[19].
• PHF11is associated with immunoglobulin E levels and asthma, located on chromosome 13q14^[20].
• A novel asthma susceptibility gene has been identified onchromosome 1qter ^[21].
• IRAK-M (IRAK3)is involved in the pathogenesis of early-onset persistent asthma^[22].
• PCDH1 has been identified as a susceptibility gene for bronchial hyperresponsiveness ^[23].
• Other implicated genes include PDE4D, CHI3L1, DPP10, GPR154 (NPSR1), OPN3, and HLA-G ^[17].

The chromosome 17q21 locus is strongly associated with asthma, particularly in childhood-onset cases^[16]. Studies also suggest that asthma is heterogeneous, with later-onset cases being more influenced by the Major Histocompatibility Complex (MHC) than childhood-onset cases^[16].

Pathways and Mechanisms

Asthma is fundamentally a chronic inflammatory disease of the airways, characterized by recurrent episodes of wheezing, chest tightness, shortness of breath, and coughing^[24]. This airway inflammation is a primary driver of the disease’s symptoms^[24]. The development of bronchial asthma is influenced by the complex interplay between genetic predispositions and environmental factors^[24].

Molecular genetics research indicates that specific genetic variants contribute to asthma susceptibility by altering key biochemical pathways that are integral to lung function^[24]. These genetic effects can manifest through changes in gene expression. Studies utilize approaches such as whole-genome gene expression profiling and the identification of cis- and trans-acting expression quantitative trait loci (eQTLs) to understand how genetic variations regulate gene activity. Further mechanistic insights are gained by constructing gene networks and identifying enriched biological pathways, which highlight interconnected genes and their functional roles in asthma.

Beyond inflammation and genetic regulation, other physiological pathways are implicated. Insulin, for example, has been shown to induce contraction in airway smooth muscle^[25]. This suggests a direct link between insulin signaling and the physiological changes in the airways during asthma, potentially connecting asthma with metabolic conditions^[26]. The relationship between inflammation and metabolic health is further supported by findings that inflammation, such as that induced by Semaphorin3E, can contribute to insulin resistance^[27]. These interactions underscore the multifaceted nature of asthma pathology, involving both inflammatory and metabolic pathways.

Pharmacogenetics of Asthma

Pharmacogenetics investigates how an individual’s genetic makeup influences their response to medications. In asthma, understanding this variability can lead to more effective therapeutic interventions^[28].

Research has explored the genetic architecture of asthma intervention response using a genome-wide association study (GWAS) involving 120 participants who inhaled multiple doses of glucocorticoids^[28]. This study utilized a mechanistic model that integrated pharmacodynamic properties of drug reactions to analyze GWAS data, enhancing the understanding of how genetics influence asthma treatment^[28].

Genetic Influences on Drug Response

The pharmacodynamic model identified five loci with genome-wide significance associated with dose-dependent response to inhaled glucocorticoids, measured as %FEV1 (forced expiratory volume in 1 second)^[28]. Many of these loci are mapped to metabolic genes linked to lung function and asthma risk^[28]. All five detected genetic variations showed a recessive effect, meaning that individuals homozygous for the mutant alleles primarily drive the variability in %FEV1 ^[28].

These five genetic variations demonstrated good replication across three independent clinical trial populations for the same phenotype ^[28]. Generally, the mutant alleles at most of these genetic variations tended to increase the pulmonary function of asthma participants by 30–300% after inhaled glucocorticoid treatment compared to wild-type alleles, though the expression of the mutant might be masked by the wild-type allele^[28]. For example, specific variations like chr6 rs6924808 and chr11 rs1353649 showed significant associations with glucocorticoid response, with p-values of 6.661 × 10−16 and 5.670 × 10−11, respectively, when an optimal genotypic model was applied ^[28].

In another study, Tantisira et al. observed that homozygotes for a mutant allele at chr7 rs37972 displayed a 120–330% decrease in lung function through glucocorticoid treatment compared with the wild-type homozygote. The heritability of glucocorticoid response explained by individual genetic variations in these studies was notably larger than for disease and physiological traits, possibly because drug response is an evolutionarily “young” trait^[28].

Clinical Implications

By integrating genetic and epigenetic observations, these findings can help in determining and designing optimal doses for individual asthma patients^[28]. This personalized approach aims to maximize drug efficacy for pulmonary function response while minimizing potential drug toxicity ^[28].

Variants

The Major Histocompatibility Complex (MHC) on chromosome 6 is the most significant genetic region influencing asthma susceptibility, specifically through genes that regulate immune recognition like HLA-DQA1, HLA-DQB1, and HLA-DRB1. Variants such asrs9272545 (HLA-DQA1) and rs2647025 (HLA-DQB1) modify how the immune system presents antigens, leading to the hypersensitivity seen in asthma and allergic rhinitis [5]. This region’s influence extends to complex gene interactions; intergenic variants linking HLA-DQA1 to HLA-DQB1 (e.g.,rs17843577 ) or HLA-DRB1 (e.g., rs9270911 ), and those near the pseudogene MTCO3P1 (e.g., rs7755224 ), affect the regulation and expression of these critical immune components [16]. Additionally, variants near HLA-DQB2 and HLA-DOB (e.g., rs7749543 ) are implicated in peptide processing, further refining the immune system’s response to environmental triggers [5]. Beyond immune recognition, genetic variants in cytokine signaling and airway epithelial function drive the inflammatory pathways of asthma. The IL1RL1 and IL18R1 genes, which encode receptors for inflammatory signals, harbor variants likers3771180 that are associated with eosinophil levels and asthma risk [6]. These receptors are activated by “alarmins” regulated by loci near IL33 (linked to GTF3AP1, e.g.,rs992969 ) and TSLP (linked to BCLAF1P1, e.g., rs1837253 ), which trigger the allergic cascade following airway stress [13]. Furthermore, the GSDMB gene on chromosome 17q21, containing variants such as rs2305479 , plays a distinct role in airway remodeling and epithelial cell death (pyroptosis), marking a critical pathway for asthma severity independent of classical allergy mechanisms [17].

Key Variants

RS ID	Gene	Related Traits
rs9272545 rs9272346 rs28383454	HLA-DQA1	Eczematoid dermatitis, allergic rhinitis asthma
rs17843577 rs28798705 rs28407950	HLA-DQA1 - HLA-DQB1	asthma
rs9270911 rs3104412 rs9271365	HLA-DRB1 - HLA-DQA1	podoconiosis clostridium difficile infection inflammatory bowel disease, vital capacity FEV/FVC ratio, inflammatory bowel disease asthma
rs7755224 rs1694112 rs79870097	HLA-DQB1 - MTCO3P1	asthma
rs3771180 rs72823635 rs72823641	IL1RL1, IL18R1	asthma eosinophil percentage of leukocytes
rs7749543 rs9276643 rs2621363	HLA-DQB2 - HLA-DOB	susceptibility to shingles measurement Eczematoid dermatitis, allergic rhinitis asthma
rs2305479 rs921650 rs1008723	GSDMB	asthma Inhalant adrenergic use measurement
rs992969 rs7848215 rs3939286	GTF3AP1 - IL33	asthma PHF-tau measurement Glucocorticoid use measurement Inhalant adrenergic use measurement eosinophil count
rs1837253 rs10455025 rs62375550	BCLAF1P1 - TSLP	eosinophil percentage of leukocytes eosinophil count eosinophil percentage of granulocytes asthma allergic disease
rs2647025 rs9273410 rs201184533	HLA-DQB1	asthma

Frequently Asked Questions About Asthma

These questions address the most important and specific aspects of asthma based on current genetic research.

---

1. Will my children definitely inherit my asthma?

Not necessarily. While asthma has a strong genetic component, with heritability estimates ranging significantly, it’s not solely determined by your genes. Your children inherit a predisposition, but whether they develop asthma depends on a complex interplay of both genetic factors and environmental exposures they encounter throughout their lives.

2. Why do I have asthma, but my sibling doesn’t, even with the same parents?

Asthma is influenced by many genes, each contributing a small effect, alongside environmental factors. Even with similar genetic backgrounds, slight differences in the specific genetic variants inherited or different environmental exposures can lead to one sibling developing asthma and the other not. It’s a complex puzzle, not a simple “on/off” switch from a single gene.

3. Does my family’s ethnic background affect my asthma risk?

Yes, your ethnic background can influence your asthma risk. Genetic variants that contribute to asthma can differ in frequency and impact across various ancestral populations. This is part of why studies show disparities in asthma rates and severity among different racial and ethnic groups, like those observed in European-Americans versus African-Americans or Hispanic-Americans.

4. Can my daily habits really change my genetic asthma risk?

While you can’t change the genes you inherited, your daily habits and environment significantly interact with your genetic predispositions. Asthma is a multi-factorial disease, meaning lifestyle choices and environmental exposures can profoundly influence whether your genetic risk factors are “activated” or how severely they impact your symptoms. Effective management can greatly improve your quality of life.

5. Why do some asthma treatments seem to work better for others?

Response to asthma medications can vary significantly between individuals and across different racial/ethnic groups. This disparity is thought to arise from a combination of factors, including differences in lifestyle, socioeconomic status, and potentially underlying population genetic variations that affect how your body processes or responds to specific drugs.

6. Why is it so hard to figure out what exactly causes my asthma?

Pinpointing the exact cause of your asthma is challenging because it’s driven by a complex interplay of many genetic factors, each with a small effect, and environmental triggers. A significant portion of asthma’s genetic influence, often called “missing heritability,” remains unexplained, meaning current research hasn’t fully captured all the intricate genetic and environmental interactions involved.

7. Does where I live make my asthma worse because of my genes?

Yes, your genes and environment, including your living location, interact significantly. Your genetic predispositions can make you more susceptible to specific environmental triggers present in your area, such as allergens, pollution, or even socioeconomic conditions. This complex gene-environment interaction can influence both the onset and severity of your asthma symptoms.

8. Are people from certain backgrounds more likely to get severe asthma?

Yes, there are notable disparities in asthma prevalence, morbidity, and mortality across different racial and ethnic groups. For instance, in the USA, African-Americans and Hispanic-Americans often experience higher rates and more severe outcomes. These differences are influenced by a mix of lifestyle, socioeconomic factors, and underlying population genetic variations.

9. Would a personal DNA test tell me my exact asthma prognosis?

Not entirely. While genetic research, like genome-wide association studies, has identified some genetic variations linked to asthma, these currently explain only a small fraction of the overall risk. A personal DNA test might show some predispositions, but it won’t give you a complete picture or exact prognosis due to the complex nature of asthma and the “missing heritability.”

10. Can I really overcome my strong family history of asthma?

While a strong family history indicates a genetic predisposition, it doesn’t mean asthma is inevitable or unmanageable. Asthma is influenced by both genetics and environmental factors. By actively managing environmental triggers, adopting healthy habits, and adhering to effective treatment plans, you can significantly reduce symptoms and improve your quality of life, even with a strong genetic background.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Masoli, M., Fabian, D., Holt, S., & Beasley, R. (2004). The global burden of asthma: executive summary of the GINA Dissemination Committee report.Allergy, 59.

[2] Duffy, D. L., Martin, N. G., Battistutta, D., Hopper, J. L., & Mathews, J. D. (1990). Genetics of asthma and hay fever in Australian twins.American Review of Respiratory Disease, 142(6), 1351–.

[3] Bousquet, J., Bousquet, P. J., Godard, P., & Daures, J. P. (2005). The public health implications of asthma.Bulletin of the World Health Organization, 83(7), 548–554.

[4] Barnett, S. B., & Nurmagambetov, T. A. (2011). Costs of asthma in the United States: 2002-2007.Journal of Allergy and Clinical Immunology, 127(1), 145–152.

[5] Ferreira, Manuel A. R. et al. “Eleven variants associated with the risk of having asthma with hay fever at the genome-wide significance level (P ≤ 3 × 10−8).”Nature Genetics, vol. 43, no. 10, 2011, pp. 1009-1016.

[6] Cookson, William O. C. et al. “Genome-Wide Association Study of Asthma.”The New England Journal of Medicine, vol. 360, no. 26, 2009, pp. 2619-2628.

[7] Becker, R. J. “Diagnostic criteria of bronchial asthma.”South Med J, vol. 56, 1963, pp. 419–420.

[8] Tantisira, K. G., et al. “Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma.”J Allergy Clin Immunol, vol. 117, 2006, pp. 1264–1271.

[9] Littner, MR, et al. “Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.”Chest, vol. 128, 2005, pp. 1128–35.

[10] van Dalen, C, et al. “Suitability of forced expiratory volume in 1 second/forced vital capacity vs percentage of predicted forced expiratory volume in 1 second for the classification of asthma severity in adolescents.”Arch Pediatr Adolesc Med, vol. 162, 2008, pp. 1169–74.

[11] Wu, AC, et al. “Predictors of symptoms are different from predictors of severe exacerbations from asthma in children.”Chest, vol. 140, 2011, pp. 100–7.

[12] Nieminen, M. M., et al. “A population-based study of bronchial asthma in adult twin pairs.”Chest, vol. 100, 1991, pp. 70–5.

[13] Ober, C., et al. “The genetics of asthma and allergic disease: a 21st century perspective.”Immunological Reviews, vol. 242, 2011, pp. 10–30.

[14] Nishimura, K. K., et al. “Early-life air pollution and asthma risk in minority children. The GALA II and SAGE II studies.”American Journal of Respiratory and Critical Care Medicine, vol. 188, 2013, pp. 309–18.

[15] Barnes, P. J. “Immunology of asthma and chronic obstructive pulmonary disease.”Nat Rev Immunol, vol. 8, 2008, pp. 183–192.

[16] Nicolae, D., et al. “A comprehensive association study of asthma and related traits in a European ancestry population.”PLoS Genetics, vol. 5, no. 8, 2009, e1000623.

[17] Kabesch, M. “Novel asthma-associated genes from genome-wide association studies: what is their significance?”Chest, vol. 137, 2010, pp. 909–915.

[18] Vercelli, D. “Discovering susceptibility genes for asthma and allergy.”Nat Rev Immunol, vol. 8, 2008, pp. 169–182.

[19] Van Eerdewegh, P., et al. “Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness.”Nature, vol. 418, 2002, pp. 426–30.

[20] Zhang, Y., et al. “Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma.”Nat Genet, vol. 34, 2003, pp. 181–6.

[21] White, J. H., et al. “Identification of a novel asthma susceptibility gene on chromosome 1qter and its functional evaluation.”Hum Mol Genet, vol. 17, 2008, pp. 1890–903.

[22] Balaci, L., et al. “IRAK-M is involved in the pathogenesis of early-onset persistent asthma.”Am J Hum Genet, vol. 80, 2007, pp. 1103–14.

[23] Koppelman, G. H., et al. “Identification of PCDH1 as a novel susceptibility gene for bronchial hyperresponsiveness.” Am J Respir Crit Care Med, vol. 180, 2009, pp. 929–35.

[24] SM, Sen S, Rodriguez-Santana JR, Bustamante CD, Williams LK, Gilliland FD, Gauderman WJ, Kumar R, Torgerson DG, Burchard EG. “Genetic ancestry influences asthma susceptibility and lung function among Latinos.”J Allergy Clin Immunol, vol. 135, 2015, pp. 228–35.

[25] Schaafsma D, Gosens R, Ris JM, Zaagsma J, Meurs H, Nelemans SA. “Insulin induces airway smooth muscle contraction.”Br J Pharmacol, vol. 150, 2007, pp. 136–42.

[26] Singh S, Prakash YS, Linneberg A, Agrawal A. “Insulin and the lung: connecting asthma and metabolic syndrome.”J Allergy (Cairo), vol. 2013, 2013, p. 627384.

[27] Shimizu I, Yoshida Y, Moriya J, Nojima A, Uemura A, Kobayashi Y, Minamino T. “Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity.”Cell Metab, vol. 18, 2013, pp. 491–504.

[28] Wang, et al. “Pharmacogenomics of Asthma Intervention: A Mechanistic Model for Dose-Dependent Drug Response.”Pharmacogenomics Journal, 26 Sept. 2018.